Astra Zeneca today filed an sNDA (an NDA to expand the number of indications for which the drug may be prescribed "on label") for Seroquel for the treatment of the depressive phase (most of the time for BP II) of bipolar disorder.

The data looks good, and approval should go quickly because the drug already has toxicology etc data.

Study showed a statistically significant decrease in depression scores that continued to improve over the course of the study.